Cardiovascular disease (CVD)

Published on 02/03/2015 by admin

Filed under Internal Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1494 times

Chapter 10 Cardiovascular disease (CVD)

Reducing risk factors

In the management of all of these risk factors an integrated approach to the treatment of CVD is required, which includes mind–body medicine, nutrition, supplements and exercise.

For treatment and prevention of hyperlipidaemia see Chapter 18.

For treatment and prevention of hypertension see Chapter 19.

Obesity

A distinct relationship between body weight, blood pressure and CVD have been well documented, and the relative risk of developing hypertension, a risk factor for CVD, increases as body mass index (BMI) increases.4 Modest weight loss of approximately 10% of body weight can normalise blood pressure. A recent review of the Trials Of Hypertension Prevention (TOHP) phase II revealed that a weight loss of approximately 5 kg can result in a significant reduction in blood pressure.5 Advice about weight loss is essential. Maintaining weight loss is the greatest difficulty faced by patients. A healthy diet and regular exercise are essential for maintaining ideal BMI.

Recently it has been reported that people lose weight by just eating fewer calories, regardless of where those calories come from.6, 7 In this US study it was reported that after 2 years, 811 overweight adults randomised to 1 of 4 heart-healthy diets, each emphasising different levels of fat, protein, and carbohydrates, showed similar degrees of weight loss. On average, participants in the study lost 6 kg in 6 months, but gradually began to regain weight after 12 months, regardless of diet group. Briefly, the diets tested in the study included the same types of foods, but in different proportions, and were tailored to patients such that overall calorie consumption was reduced by approximately 750 calories per day, with each diet including a different macronutrient composition:

Prevention

The public and health professionals must implement comprehensive preventative programs that address lifestyle and nutritional issues if it is to achieve a significant reversal of the increasing incidence of CVD worldwide.1 The major focus is currently on treatment of CVD, however, there is increasing interest in dealing with the factors responsible for this disease, but more needs to be done. More is known about the factors responsible for CVD than most other diseases and hence it lends itself well to interventions with primary and secondary prevention.

The Australian Heart Foundation website provides extensive public and health professional information on risk factors, prevention and lifestyle strategies for hypertension and CVD.8

Lifestyle

Many studies consistently demonstrate greater reduction of cardiac risk factors by implementing positive lifestyle behavioural changes such as avoiding smoking, stress management, dietary changes, and physical activity.9, 10

Combining a low-risk diet and healthy lifestyle behaviour, such as moderate amounts of alcohol, being physically active, not smoking, and maintaining a healthy weight, can significantly reduce the risk of myocardial infarction according to a population-based prospective study of 24 444 post-menopausal women diagnosed with cancer, CVD and diabetes mellitus.11 Specifically the protective lifestyle factors included: not smoking, waist-hip ratio less than the 75th percentile (< 0.85), being physically active (at least 40 minutes of daily walking or bicycling and 1 hour of weekly exercise) and a dietary pattern characterised by a high intake of vegetables, fruit, wholegrains, fish, and legumes, in combination with moderate alcohol consumption (no more than 5 g of alcohol per day; a standard glass of wine contains 11g of alcohol). The authors concluded that most myocardial infarctions are preventable through lifestyle changes.

The Ornish program has shown that it is possible to reverse CVD in selected patients using a program that incorporates aspects to do with the causes of this disease, namely, psychological factors, nutritional factors and exercise.12 The Ornish program includes a very low fat, whole food, vegetarian diet rich in complex carbohydrates and low in simple sugars (supplemented with vitamin B12) along with regular walking, smoking cessation and stress management techniques. This program produced a 91% reduction in the frequency of angina and there was regression of coronary atherosclerosis after only 1 year and even more regression after 5 years in select patients.3 The control group had increased coronary atherosclerosis and increased angina after 1 year and even more stenosis after 5 years. This program has been criticised because patients can have difficulty in maintaining such a low-fat diet, plus tended to have increased serum triglycerides and decreased high density lipoprotein (HDL). Dietary fish or fish oil supplementation can be used to normalise triglycerides and have been demonstrated to improve survival in patients with coronary artery disease and hypercholoesterolaemia.13, 14

Despite an increasing interest by various public health authorities to recommend lifestyle and dietary changes to population groups, the general health of those groups is deteriorating as reflected by a decrease in physical activity and a massive increase in the problem of overweight and obesity.2

In recent reviews it has been shown that people in developed countries just do not consume the recommended daily allowance of 6–8 helpings of fruit and vegetables.15, 16 Hence the recommendations have included supplementation with good multivitamin and mineral preparations.5 In an article in the Heart Lung journal, Lewis encourages doctors to utilise nutritional supplements to assist in the management of patients with CVD.17 In his article he cites the benefits that are to be gained from patients adopting lifestyle–nutritional changes that can easily be annexed to traditional treatment options, and explains why it is necessary. A unique part of this article is how he describes the 3 distinct morphological processes of CVD and explains the difference between primary and secondary prevention. The 3 distinct pathological processes are plaque growth, which begins in adolescence and involves oxidation of low-density lipoprotein (LDL) cholesterol, plaque rupture, and clot formation which leads to immediate coronary artery occlusion and arrhythmias which result from myocardial ischemia. Understanding the timing of the distinct pathological processes allows for the most appropriate use of certain nutritional supplements.

Certainly the inappropriate timing of nutritional supplement use could explain why supplements may not be effective in some CVD studies. Despite this there is increasing evidence that supplements such as vitamins, minerals and omega-3 fats are useful in the prevention and management of CVD.

Family lifestyle intervention for children

Obesity in children and adolescence is a growing problem in virtually every developed country and the prevalence is rising. Extrapolation from current US data found adolescent overweight is projected to increase the prevalence of obesity in adulthood (35-year-olds) in 2020 to 30–37% in men and 34–44% in women, which will consequently increase the incidence and risk of coronary heart disease (CHD), cardiac events and deaths in young adults and the middle aged.18 Management of the child to lose weight needs to focus on lifestyle interventions such as modifying diet, physical activity and behavioural therapies within the whole family. A recent Cochrane review evaluated the efficacy of lifestyle, drug, and surgical interventions to treat obesity in childhood.19 A total of 12 studies were directed at lifestyle interventions (physical activity and sedentary behaviour), 6 studies addressed diet and 36 evaluated behaviourally oriented treatment programs. This review concluded that family-based lifestyle interventions that modify diet and physical activity and include behavioural therapy can significantly help obese children lose weight and maintain that loss for at least 6 months compared to standard care or self-help alone.

Breast-feeding

A recent study investigated the relationship between duration of lactation and maternal incident myocardial infarction.20 It was reported that compared with parous women who had never breastfed, women who had breastfed for a lifetime total of 2 years or longer had 37% lower risk of CHD, adjusting for age, parity, and stillbirth history.

Mind–body medicine

Participants of a large prospective population-based cohort study of 6025 adults without CHD followed for a mean of 15 years demonstrated a dose-response relationship between emotional vitality (defined as a positive state associated with feelings of enthusiasm, energy, and interest) and reduced risk of CHD.21 The authors concluded: emotional vitality may protect against risk of CHD in men and women.

Depression and social isolation

Depression and social isolation are strongly associated with CVD and can have a major influence on prognosis.22 The impact of depression and social isolation is of a similar order to conventional risk factors such as smoking. A study of up to 500 patients hospitalised for acute coronary syndrome found that the onset of depression immediately following an acute cardiac event significantly influenced the long-term survival and illness severity of the patient.23

The Heart and Soul Study is a prospective cohort study of 1017 outpatients with stable CHD followed for an average period of 4.8 years.24 After adjustment for co-morbid conditions and disease severity, depressive symptoms were associated with a significant 31% higher rate of cardiovascular events compared with those with no depression, which was largely explained by negative behaviour patterns such as physical inactivity.

Worrying and mental stress are also a risk factor for cardiac events, CHD and accelerates atherosclerosis according to studies.25, 26

Social isolation is a difficult problem to deal with and requires taking an extensive family history about family and friends and usually assistance and support from other health professionals and support groups.

A cohort of 13 000 women and men demonstrated a doubling of the coronary risk factor with social deprivation over a 10-year period.27 Having a close friend for regular support when needed can reduce the risk of subsequent myocardial infarction by 50%.28

An expert working group for the National Heart Foundation of Australia did a systematic review of the literature and found strong and consistent evidence to indicate depression, social isolation and lack of quality social support is associated with the causes and prognosis of CHD.29

Owning a pet may help pet owners survive longer after a heart attack and reduces heart rate variability according to a US study of 100 patients following a myocardial infarction when compared with non-pet owners.30

Social support

The Framingham Heart Study social network followed up 4739 individuals over a 10-year period and found that people’s degree of happiness was determined by the happiness of others whom they are connected with, being surrounded by happy people and geographical proximity in close range.31 For example, a happy friend who lives within 1.6 km increases the probability that a person is happy by 25%. Similar effects were seen with partners, siblings who live close and next door neighbours, but not seen between co-workers. Effects are not seen between co-workers and happiness declined with time and geographical separation.

Unhappy marriage

An interesting 5-year follow-up study found that women with CHD had a 3-times higher chance of major cardiac events and death over the 5 years if they had a stressful marital or cohabiting relationship.32 Negative relationships can increase the likelihood of cardiac events and in 1 study this risk was estimated to be as high as 34% compared with low level negativity.33, 34 A good marriage also improved survival in women with heart failure.35

Stress

Stress has been identified as a causative factor in hypertension.37 Stress is also known to precipitate cardiac events and is considered a more important marker of myocardial infarction than hypertension and diabetes. For example, viewing a stressful soccer match doubles the risk of an acute cardiovascular event such as risk of angina, myocardial infarction or arrhythmia.38 A sudden emotional shock such as the loss of a loved one can cause symptoms of myocardial infarction even in patients with no clinically significant coronary disease39, including in young people by triggering coronary vasospasm.40

A review of the literature has found stress impacts adversely on health and on longevity and can increase the risk of stroke.41, 42 A study found that for women who are content with their lives at home and at work, atherosclerosis can actually regress, but progresses in those experiencing ongoing stress, independent of other CVD risk factors such as age, smoking, hypertension and HDL levels at baseline.43 A Lancet review found a strong and consistent association between stress and CVD.44

Work stress

A prospective cohort of almost 1000 middle-aged patients following a myocardial infarction demonstrated chronic work stress was associated with a twofold increased risk of CVD 2–6 years after returning to work compared with low job stress.45 In another study of London civil servants, being in a ‘just’ or fair workplace reduced the risk of CHD by 35% compared to employees who described their work as being ‘unjust’.46 Also, a sense of ‘lack of control’ at work can increase the risk of CHD.47

Sleep

Siesta (afternoon nap)

Greek researchers demonstrated a daily siesta is protective towards CVD and coronary mortality according to a large scale cohort study of 23 681 individuals.54 After excluding confounders, occasional napping reduced risk of coronary mortality by 12%, and systematic napping by up to 37%, particularly in working men, compared with non-nappers. However, a recent report warns that excessive daytime sleepiness is an independent risk factor for total and cardiovascular-related mortality in elderly individuals.55

Sleep deprivation

Lack of sleep is being identified as a new risk factor for coronary artery disease, including calcification of the arteries. A US study of 500 healthy middle-aged men and women found that just 1 hour of extra sleep per night reduced the risk of calcification of the arteries (coronary artery calcification was measured by computed tomography) by an average of 33%.56 This association was more pronounced in women. The study adjusted for all other risk factors such as age, sex and BMI. The researchers postulated that blood pressure drops during sleep, so insufficient or poor quality sleep may interfere with the decline in blood pressure, increasing the risk of CVD.

A Japanese study of hypertensive patients also found after adjusting for confounders, short sleep duration significantly increases the risk of CVD compared with normal sleep duration.57 The researchers’ conclude that lack of sleep is an independent predictor of cardiovascular events.

Snoring and obstructive sleep apnoea (OSA)

OSA is a well-recognised risk factor for CVD and mortality, including nocturnal sudden cardiac death.58, 59 Sleep units are now well established in a number of hospitals, especially in developed countries, to help identify this problem and provide nocturnal oxygen inhalation therapy for those with confirmed sleep apnoea. Researchers found that sudden cardiac death occurred overnight significantly more in subjects with severe OSA (46%) than those without OSA (21%) or compared with sudden cardiac death victims in the general population (16%).60 An observational cohort study of 110 subjects who underwent bilateral carotid and femoral artery ultrasounds to quantify atherosclerosis, demonstrated snoring is a significant independent risk factor for carotid (not femoral) artery atherosclerosis; the risk factor increasing with degree of severity of snoring.61

Sunshine and vitamin D

Sunshine exposure, specifically solar ultraviolet B, is the major source for vitamin D production by the human body. Epidemiological studies indicate lack of ultraviolet light exposure may contribute to geographic and racial blood pressure differences, CVD and CVD mortality. 6266 Deaths due to CVD are more common in the winter and at higher or lower latitudes.67 Vitamin D deficiency is common worldwide and epidemiological evidence is associated with increased risk of CVD, hypertension, metabolic syndrome, heart disease, congestive heart failure, myopathy, chronic vascular inflammation, peripheral artery disease, hyperparathyroidism, autoimmune diseases, diabetes, cancer and all-cause mortality as well as many other diseases (see also Chapter 30, osteoporosis).6876 The proposed mechanisms include an increase in parathyroid hormone and activation of the rennin-angiotensin-aldosterone system. The hormone 1,25 hydroxy-vitamin D is involved in the production of renin which regulates blood pressure.

In a large prospective study the researchers demonstrated that deficiency in either 25-hydroxyvitamin D and 1,25-hydroxyvitamin D were equally associated with increase in all-cause mortality and CVD mortality.77 Serum parathyroid (PTH) levels increase when vitamin D levels fall below 75mmol/L. Slightly enhanced PTH levels are associated with CVD morbidity and mortality, as seen in renal patients and peripheral artery disease.7880

Also, studies demonstrate vitamin D deficiency is linked with elevated C-reactive protein levels which are associated with increased cardiovascular events.81 Whilst an observation study did not demonstrate an association of CVD and low levels of 1,25 hydroxy-vitamin D in patients with myocardial infarction,82 community-based studies have shown a strongly positive correlation with low vitamin D contributing to the pathogenesis of congestive cardiac failure and myocardial infarction.83, 84 A recent study of over 3200 patients referred for coronary angiogram and assessed over an 8-year period, found a strong independent correlation with low serum 25(OH)vitamin D (7.6–13.3ng/ml) and double risk of cardiovascular mortality.85 Overall the weight of evidence points strongly towards an association of CVD and lack of sunshine and vitamin D deficiency. Due to its widespread benefit in many areas of health, safe sunshine exposure of at least 30 minutes daily, with walking, would appear to be of great benefit to anyone to ensure normal vitamin D levels and for the prevention and management of CVD.

Environment

Physical activity

Yoga

Yoga has been recommended as efficacious in the primary and secondary prevention of ischaemic heart disease and post-myocardial infarction patient rehabilitation.99 There are several studies that demonstrate yoga can reduce cardiovascular reactivity to stress, a factor that is strongly associated with cardiovascular risk.100 Controlled studies have demonstrated that yoga can reduce blood pressure (see also Chapter 19, hypertension) and hence cardiovascular risk.101105

Qigong

Several randomised controlled trials have evaluated qigong interventions from multiple perspectives, specifically targeting older adults.101 In adults, particularly the aged, this form of physical activity can lead to significant improvements in physical functioning, mood, weight, and in the reduction of cardiovascular risk factors.101 Improvements in cardiovascular factors such as systolic and diastolic blood pressure, increased pre-ejection fraction and heart rate variability have been documented.108111

Physical therapies

Musculoskeletal therapy

Some complementary and alternative physical therapies show promise in cardiac rehabilitation.112 A recent study with stroke patients reported that single-modality exercises targeted at existing impairments do not optimally address the functional deficits of walking but did ameliorate the underlying impairments.113 Also the study reported that the underlying cardiovascular and musculoskeletal impairments were significantly modifiable years after stroke with targeted robust exercise. In another recent study it was reported that regular arm aerobic exercise lead to a marked reduction in systolic and diastolic blood pressures and an improvement in small artery compliance.114 The study further concluded that arm-cycling was a logical option for hypertensive patients who choose to support blood pressure control by sports despite having coxarthrosis, gonarthrosis, or intermittent claudication.

Acupuncture

An early report concluded that there were sufficient clinical studies in humans that demonstrate acupuncture can exert significant effects on the cardiovascular system and provide effective therapy for a variety of cardiovascular ailments.115 In a recent study of acupuncture and cardiac arrhythmias; the 8 eligible studies reviewed demonstrated that 87–100% of participants converted to normal sinus rhythm after acupuncture. Hence it was concluded that acupuncture seemed to be effective in treating several cardiac arrhythmias, but limited methodological quality of the studies necessitates better-controlled clinical trials to be performed.116

Nutritional influences

Worldwide dietary patterns

Diet is a modifiable risk factor for CVD. The INTERHEART study involving 52 countries identified 3 major dietary patterns: Oriental (high intake of tofu, soy and other sauces), Western (high in fried foods, salty snacks, eggs, and meat), and prudent (high in fruit and vegetables).118 The study demonstrated an inverse association between the prudent pattern and acute myocardial infarction (AMI); the Western pattern showed a U–shaped association with AMI; the Oriental pattern demonstrated no relationship with AMI. The researchers concluded that the unhealthy dietary intake increases the risk of AMI globally and accounts for about 30% of the population-attributable risk.

The INTERGENE population study of 3452 participants (aged 25–74 years) identified dietary patterns associated with CVD risk factors, obesity and metabolic syndrome.119 Unhealthy food patterns were characterised by high consumption of energy-dense drinks and white bread, and low consumption of fruit and vegetables. Healthy food patterns was distinguished by more frequent consumption of high-fibre and low–fat foods and lower consumption of products rich in fat and sugar.

A recent Cochrane review of the literature also demonstrates dietary advice lowers prevalence and incidence of CVD.120

The Seven Countries study demonstrated that population-related factors significantly affect the risk of CVD and that diet was directly related to the risk of developing coronary artery thrombosis that lead to heart attacks.120 Dietary factors were far more significant than other risk factors, as variations in cholesterol and incidence of smoking in men from one country to another did not account for the differences seen in CVD. This study also demonstrated lower levels of many cancers, dementia and all-cause mortality in people who adhered closely to their traditional Mediterranean or Japanese diets.

Olive oil

A study of patients with stable CHD aimed to identify the effects of olive oil on cardiac risk factor blood parameters.127 The placebo-controlled, cross-over, trial randomised patients with either raw daily dose of 50ml of virgin olive oil or refined olive oil over a total 6-week period and found reduction in the inflammatory markers interleukin-6 and C-reactive protein with virgin olive oil intervention compared with refined olive oil group, but no changes observed with glucose and lipid profile.

The polymeal

The polymeal, as opposed to the polypill, are the foods identified to be cardio-protective. The polymeal is far safer and more natural and can reduce the risk of CVD by more than 75% (see Table 10.1).128 Taking the polymeal daily significantly increased total life expectancy far greater in men than in women.

Table 10.1 Effect of ingredients of polymeal in reducing risk of CVD

Ingredients Average percentage reduction (95% CI) in risk of CVD source NHMRC level of evidenceMA = meta-analysis; RCT = randomised controlled trial
Wine (150ml/day) 32 % MA
Fish (114g x 4 times/week) 14% MA
Dark chocolate (100g/day) 21% RCT
Fruit and vegetables (400g/day) 21% RCT
Garlic (2.7g/day) 25% MA
Almonds (68g/day) 12.5% RCTs
Combined effect 76% (63 to 84%)  

(Source: adapted from Franco et al. 2005)128

A recent meta-analysis of 12 prospective cohort studies of over 1.5 million participants over a 3–18 year period affirms the health benefits of the Mediterranean diet.129 Stricter adherence to the diet conferred significant cardiac protection, and led to further reductions in risk of all cause-mortality, death from CVD, as well as cancer and degenerative diseases compared with low adherence. Adherence to the Mediterranean diet can also significantly reduce the risk for type 2 diabetes.130

High fibre diet

Total dietary fibre (cereal, fruit, and vegetable) is associated with a 14% reduction in the risk of all coronary events and a 27% decrease in the risk of coronary death.134 Further research confirms its protective role towards CVD according to analysis of the Physicians Health Study I, that demonstrated consumption of wholegrain cereal at breakfast and high dietary fibre are associated with less prevalence of hypertension, lower risk of heart failure and reduced incidence of myocardial infarction.135 Intakes of wholegrain fibre are inversely associated with progression of atherosclerosis, according to a study on post-menopausal women with coronary artery disease.136 Oatmeal for breakfast also reduces the risk of CHD.137

Dietary fibre also improves glycaemic control in diabetics, as well as lowering cholesterol/low-density lipoprotein LDL.

Vegetarian diet

A vegetarian diet has been reviewed for its beneficial and adverse effects in various medical conditions.139 It was concluded in that study that the beneficial effects may be due to the diet (consisting of monounsaturated and polyunsaturated fatty acids, minerals, fibre, complex carbohydrates, antioxidant vitamins, flavanoids, folic acid and phytoestrogens) as well as the associated healthy lifestyle that vegetarians pursue. There were few adverse effects reported and these consisted of increased intestinal gas production and a small risk of vitamin B12 deficiency.

A more recent report conducted over a mean of 8.1 years suggested a dietary intervention that reduced total fat intake and increased intakes of vegetables, fruits and grains did not significantly reduce the risk of CHD, stroke, or CVD in post-menopausal women and achieved only modest effects on CVD risk factors, suggesting that more focused dietary and lifestyle interventions may be needed to improve risk factors and reduce CVD risk.140

Fish and omega–3 polyunsaturated fatty acids

The benefits of eating just 1–2 servings of fish weekly can significantly reduce the risk of coronary death, which outweighs harm from contaminant exposure from mercury and dioxins from fish intake.141 Modest intake of fish consumption compared with eating fish only once weekly substantially reduced the risk of CHD amongst middle-aged persons.142 This prospective study of nearly 42 000 Japanese people demonstrated the more fish intake the lower the risk of CVD. The group with the highest fish intake, equivalent to 180g daily, reduced the CVD risk by 40%.

A number of cohort studies demonstrate that regular consumption of fish, even just 1–2 servings weekly, is associated with reduced risk of sudden death, cardiac arrest, heart failure and atrial fibrillation, compared with those who only eat fish once monthly.143, 144, 145

Salt/sodium restriction

Data from 2 randomised trials, TOHP I and TOHP II, involved a total of 3126 participants assessed over a 10–15 year period who were randomised to a sodium reduction intervention or control for 18 months (TOHP I) or 36-48 months (TOHP II).155 The researchers found a significant reduction in risk of a cardiovascular event by up to 30% among those in the low-sodium diet intervention group compared with control group. The researchers concluded: ‘Sodium reduction, previously shown to lower blood pressure, may also reduce long-term risk of cardiovascular events’. 154

A low-salt diet is also cardio-protective in normotensive patients, as well as effectively lowering blood pressure in hypertensives. A recent study of normotensive overweight and obese adults were randomised to low or standard diet groups.155 Within 2 weeks the low-salt diet group (50nmol sodium per day) demonstrated 30% less brachial artery flow-mediated dilatation, lower systolic blood pressure and reduced 24 hour sodium excretion compared with the standard diet group. This study highlights the need to remove salt from many prepared foods and in the diet to prevent the onset of hypertension.

Cocoa and/or dark chocolate

Several studies have shown that cocoa can decrease blood pressure to a similar extent to that of pharmaceuticals.156 New research suggests 1 serving of dark chocolate (20g; not milk chocolate) every 3 days significantly reduces the levels of the inflammatory marker C-reactive protein which may help to reduce inflammation, a known risk factor for many diseases, including CVD and cancer.157 A 30-day trial demonstrated drinking a cup of cocoa daily can improve flow-mediated dilation and combat blood vessel dysfunction linked to diabetes.158 Daily consumption of 46g of dark chocolate increased blood levels of flavonoid epicatechin and significantly improved arterial function in a group of healthy volunteers.159

Alcohol

Whilst the cardio-protective properties of moderate alcohol consumption, compared with abstinence or heavy drinking, are widely recognised, this interesting study, a longitudinal-based cohort study, aimed to identify whether the benefits are experienced equally by all moderate drinkers.160 The study found a significant benefit of moderate drinking was identified amongst those with poor health behaviours (little exercise, poor diet and smokers) compared with abstinence or heavy drinking. There was no additional benefit from alcohol amongst those with the healthiest behaviour profile (>3 hours vigorous exercise per week, daily fruit or vegetable consumption and non-smokers). The authors concluded the cardio-protective benefit from moderate alcohol drinking ‘does not apply equally to all drinkers, and this variability should be emphasised in public health messages’.160 However, another large-scale US study of a cohort of 8867 men over 16 years found after adjusting for confounders, moderate levels of alcohol (5–30g per day) reduced the risk of myocardial infarction by up to 50%.161

Nutritional supplements

Antioxidants

A US cross-sectional study assessed users of a broad range of daily nutritional, herbal and dietary supplements.172 After adjustment for age, gender, income, education and BMI, supplement use was associated with optimal levels of chronic disease biomarkers (serum homocysteine, C-reactive protein) and high-density lipoprotein cholesterol and triglycerides, less likely to have sub-optimal blood nutrient levels, elevated blood pressure, high BMI and diabetes compared with non-users or multivitamin/mineral users alone.

A trial of 13 017 French adults (7876 women aged 35–60 years and 5141 men aged 45–60 years) randomised to either a single daily capsule of antioxidants (120mg of ascorbic acid, 30mg of vitamin E, 6mg of beta-carotene, 100mcg of selenium and 20mg of zinc) or a placebo over a 7.5 year period. The study found the antioxidant supplement reduced the risk of cancer and all-cause mortality in men, but not in women.173 The researchers postulated that men are more likely to have lower baseline status of certain antioxidants, especially of beta-carotene.

Vitamins E and C

There is increasing biological plausibility for the use of vitamin supplements for the prevention of CVD. Oxidised LDL cholesterol attracts and interacts with monocytes, macrophages and platelets to promote atherogenesis and also causes endothelial necrosis plus interferes with vaso-relaxation. vitamins E and C have been shown to inhibit LDL oxidation and vitamin E reduces endothelial monocyte adhesion, as well as inhibiting platelet activation.174176 Angiographic and ultrasonographic studies in humans suggest that vitamin E also inhibits the progression of atherosclerosis.8, 9, 177 Often researchers do not distinguish between the synthetic and natural forms of vitamin E which have different structures and functions. Studies in general that utilise natural vitamin E and at doses of 500IU or above have shown a benefit.178 Whereas, studies that employed a lower dose or the synthetic form of the vitamin were found to be ineffective.11 There is a known synergy between vitamin E and vitamin C plus selenium that allows for a maximum benefit.

Vitamin E is synergistic also with aspirin as they are both cyclooxygenase inhibitors which significantly increases the efficacy of aspirin therapy.179 Unfortunately, there are no primary prevention studies that have evaluated the role of natural vitamin E. Vitamin C, in addition to regenerating the antioxidant properties of vitamin E, has an anti-inflammatory action which is thought to be important in the prevention of arterial disease.180

According to the Physician’s Health Study II, a double-blind, placebo-controlled trial of high doses of synthetic vitamin E (400IU 2nd daily) with vitamin C (500mg daily), or provided alone, compared with placebo over an 8-year period was not cardio-protective and did not reduce total mortality.181 It was also concerning that the vitamin E treatment group had a marginally significant increased risk of hemorrhagic stroke, which is plausible as vitamin E is known to prolong bleeding times. It is likely the benefits of vitamin E witnessed in other trials are found with the natural forms (not synthetic).

Findings from the Women’s Antioxidant Cardiovascular study of 1450 women also demonstrated no overall benefit of either ascorbic acid (500mg/d), vitamin E (600IU every other day) and beta-carotene (50mg every other day) for CVD, although there was a marginally significant reduction in the vitamin E group in women with prior history of CVD and those randomised to both active ascorbic acid and vitamin E experienced fewer strokes.182 There are concerns with the use of synthetic vitamin E.

Vitamin B

Nicotinic acid (Niacin)

Niacin lowers LDL cholesterol as well as triglycerides plus raising HDL and lowering total cholesterol. The major drawback is that it causes flushing at high doses and can cause liver toxicity.183 A slowly released form of niacin is generally better tolerated. Further, a meta-analysis of niacin has shown that it is a safe and an effective option for dyslipidemia.184

Folate, vitamin B12, vitamin B6 and Homoceysteine

Previously only very high levels of homocystine were thought to be related to coronary artery disease. More recent data suggests that levels as low as 12mol/L may increase the risk of vascular disease.185 There is a relationship between homocysteine levels and vascular disease that is supported by epidemiological data. However, there are also negative studies. Homocysteine is an amino acid product of normal protein metabolism. Folate, vitamin B12 and vitamin B6 are all involved in the metabolism of homocysteine. Deficiencies of 1 or more of these vitamins can lead to hyperhomocysteinemia.15, 186 Folic acid in combination with vitamin B12 and vitamin B6 have emerged as potentially valuable nutrients for the prevention and treatment of atherosclerosis.16

Since the voluntary fortification of foods in Australia with folate, serum folate levels have risen and there has been a corresponding reduction of homocysteine levels in a group of 468 adults in Western Australia over a 4-year period.187

Moreover, it is of relevance that elevated homocysteine levels have also been linked with Alzheimer’s disease and hence normalisation of homocysteine levels through the use of folic acid may also provide protection from this disease.188 Further, folic acid has been shown to be extremely useful for the prevention of most congenital abnormalities,189, 190 as well as multiple cancer sites that include the cervix, large bowel and breast.18, 19, 191, 192, 193

However, there are mixed results for any cardiovascular benefit with folate and vitamin B12 supplementation even where homocysteine levels have dropped. For example, a large US study of 5442 women with CVD or with 3 or more risk factors for CVD was randomised to a daily combined pill of folate (2.5mg) and vitamins B6 (50mg) and B12 (1mg) or placebo.195 Whilst homocysteine serum levels significantly dropped by 18%, there was no reduction in deaths or cardiovascular events observed in the treatment group compared with placebo. A second large study of 3046 patients over an 8-year period, also demonstrated no preventative effect of intervention with folic acid with vitamin B6 or B12 despite significantly reducing homocysteine levels by 30% after 1 year supplementation with folic acid and vitamin B12.195 The study groups received daily oral treatment with folic acid (0.8mg) plus vitamin B12 (0.4mg) plus vitamin B6, (40mg) (n = 772); or folic acid plus vitamin B12 (n = 772); or vitamin B6 alone (n = 772); or placebo. These findings did not support the use of B vitamins as secondary prevention in patients with CAD. B group vitamins may be more appropriately indicated for primary prevention.

Vitamin K

Low dose vitamin K (K1 and K2) supplementation may protect against atherosclerosis and heart disease, including in patients taking warfarin.199, 200

According to several animal studies, patients taking warfarin are susceptible to developing atherosclerosis from calcification of the arterial walls. vitamin K2, not K1, inhibits warfarin-induced arterial calcification in animal studies.201, 202 Very low dose vitamin K2 supplementation (50–70mcg/day) may help stabilise INR fluctuations in patients with vitamin K deficiency, although this needs great care under medical supervision and dietary sources are safer.203207 vitamin K (oral or intravenous) is used to reduce excessively high INR in patients on warfarin.

Minerals

Magnesium

There has been increasing attention given to the role of magnesium and selenium in CVD. Magnesium deficiency has been shown to produce coronary artery spasm which is thought to be a cause of non-occlusive heart attacks.208 Furthermore, it has been observed that men who die suddenly of heart attacks have significantly lower levels of myocardial magnesium as well as potassium than matched controls.23

It has been suggested that magnesium should become the treatment of choice for angina that is due to coronary artery spasm. Magnesium has also been found to be helpful in the management of arrhythmias and in angina due to artherosclerosis.209 Oral magnesium therapy improves endothelial function, exercise tolerance, reduces exercise-induced chest pain and quality of life in patients with coronary artery disease.210, 211 Magnesium is known to be an effective smooth muscle relaxant. It is likely it could even have benefit for angina in the acute setting.

The Paris Prospective Study 2, a cohort of 4035 men (age 30–60 years) during an 18-year follow-up based on baseline serum mineral levels, demonstrated low serum magnesium and high serum copper, and concomitance of low serum zinc with high serum copper or low serum magnesium, contributed significantly to an increased all-cause mortality, mortality cancer risk and cardiovascular deaths in middle-aged men.212

Magnesium also helps lower blood pressure which has a favourable effect on CVD (see Chapter 19, hypertension). There is a significant inverse relationship between serum magnesium and both systolic and diastolic blood pressure.213 Meta-analysis of RCTs demonstrates it is effective for hypertension.214

Intravenous magnesium

Over the last 20 years there have been over 17 well-designed studies demonstrating that intravenous magnesium during the first hour of admission into hospital for an acute myocardial infarct (MI) can produce a favourable effect in reducing death rates.215 Magnesium infusion in 250 patients with suspected MI, resulted in a 54% reduction in mortality from cardiac disease compared with placebo.216 Its benefit in this situation relates to many properties including dilatation of the coronary arteries, reduction in peripheral vascular resistance, improving cardiac energy production, inhibiting platelet aggregation and probably most importantly improving heart rate and arrhythmia.217 Key factors in the use of intravenous magnesium are timing after onset of symptoms and timing in relation to thrombolysis, and giving the correct rate of magnesium infusion.218 Controversy surrounds the use of intravenous magnesium in acute myocardial infarction because the 2 large negative trials (ISIS-4 and MAGIC)219, 220 involving more than 64 000 patients, and therefore with stronger statistical power calculations, used a higher dose of intravenous magnesium in the first 24 hours than any of the prior positive studies. There has as yet been no published dose-related meta-analysis of intravenous magnesium in acute myocardial infarction.

Calcium

A large trial of 1471 healthy post-menopausal women (mean age 74), were randomised to either calcium supplementation alone or placebo over a 5-year period.221 Myocardial infarction, stroke and sudden death were significantly higher in the calcium group by over 50% compared with the placebo group. The researchers note the detrimental effect on CVD could outweigh any benefits on bone from calcium supplements. More studies are warranted to assess if calcium combined with magnesium and vitamin D, may offset these effects.

Fish oils / omega-3 fats

Fish oil supplements are generally well tolerated and safe. Due to the overwhelming weight of scientific evidence including meta-analyses, high dietary fish intake and fish oil supplements are now recommended for adults with cardiovascular risk factors.

Research including a meta-analysis of the literature, suggest taking just 1 capsule of fish oil supplements (1g daily) can lower resting heart rate, stabilise heart rate variability and reduce risk of fatal dysrhythmias which may explain its cardio-protective properties.226229

United States recommendations

The American Heart Association recommends that fish oil be considered for all patients who have recovered from MI.230 Moreover, the Nutrition Committee of the American Heart Association has also recommended that fish oil needs to be considered in all patients following a heart attack due to its proven benefit for reducing sudden death.231

Further, recently the American Heart Foundation carried out an extensive review of the scientific literature regarding omega-6 fatty acids and risk for CVD.232 The advisory committee concluded that based on the current evidence, from aggregate data from randomised trials, case-control and cohort studies, and long-term animal feeding experiments indicate that the consumption of at least 5–10% of energy from omega-6 PUFAs significantly reduces the risk of CHD relative to lower intakes. The data also suggested that higher intakes appear to be safe and may be even more beneficial (as part of a low-saturated-fat, low-cholesterol diet regimen).

Australian recommendations

The Australian Heart Foundation has prepared an extensive review of the literature that includes meta-analyses on the value of omega-3 PUFAs and fish in the prevention of CVD that includes cardiac disease, heart failure, myocardial infarction and stroke.233 For established CVD in an adult, the Heart Foundation recommends fish oil supplementation be strengthened to include consumption of approximately 1g Eicosapentaenoic acid (EPA) plus Docosahexaenoic acid (DHA) and >2g Alpha Linolenic Acid (ALA) daily. Other studies recommend dosage of EPA and DHA in the combined range of 800–1000mg daily for both primary and secondary prevention of CVD.234 The authors have concerns about the recommendation of linseed in bread because of the potential for damage to linseed ALA with heat. (See Table 10.2.)

Table 10.2 Australian Heart Foundation recommendations

To lower their risk of CHD, all adult Australians should: Health professionals should advise adult Australians with documented CHD to:

(Source: adapted from Australian Heart Foundation recommendations)233

Other nutritional supplements

Coenzyme Q10 (Ubiquinone)

CoQ10 is a vitamin-like nutrient. Its primary role relates to the production of energy (ATP) in the mitochondria and it also acts as an antioxidant. CoQ10 is known to have anti-hypertensive properties by normalising peripheral resistance (see Chapter 19, hypertension).

A large body of growing data supports the potential use of CoQ10 for mitochondrial diseases with heart involvement, heart failure and cardiomyopathy in both adults and children.237240

The ENDOTACT study demonstrated a positive influence of CoQ10 supplementation on human endothelial function independent of lipid lowering .241 In a study of 38 patients with coronary artery disease, they were randomised to either oral CoQ10 (300mg daily divided into 3 doses) or placebo for 1 month.242 All patients were assessed for brachial artery endothelium-dependent assessment, cardiopulmonary exercise test, and the measurement of endothelium-bound ecSOD activity (baseline and post-study). All parameters, such as endothelium-dependent dilatation and improved peak ventilation oxygen levels, statistically improved in the CoQ10 group compared with placebo.

CoQ10 can also play a role in angina treatment. CoQ10 (150mgs 3 times daily for 4 weeks) reduced the frequency of anginal episodes by over 50% and the need for nitroglycerine medication compared with patients receiving placebo.243

Statin drugs are known to adversely interact and reduce levels of CoQ10. The statins inhibit the enzyme HMG CoA reductase required for the manufacture of cholesterol in the liver, but by doing so, this blocks the substances required to produce CoQ10. Consequently this may explain the adverse effect of statins such as fatigue and muscle pain which correlates with lowering of CoQ10 levels.244 Supplementation of CoQ10 together with statins may help reduce the risk of these side-effects.

L-carnitine

L-carnitine is an endogenous molecule that is an important contributor to cellular energy metabolism. The concept of modulating the energy metabolism of the heart so as to ameliorate the performance of the dysfunctional myocardium is a firmly established notion.245 Cardiac muscle contains high levels of carnitine and many patients with CVD demonstrate low levels of carnitine.246 A recent review concluded that L-carnitine could prevent apoptosis of skeletal muscle cells and that it has a role in the treatment of congestive heart failure-associated myopathy.247 This has evolved from an emergent literature describing the clinical efficacy of L-carnitine in patients affected by heart disease248, 249, 250 albeit with some controversy.251

Further, cardiovascular function has an intimate relationship with cognition in the ageing process. Recently it has been demonstrated that oral administration of levocarnitine produces a reduction of total fat mass, increases total muscular mass, and facilitates an increased capacity for physical and cognitive activity by reducing fatigue and improving cognitive functions.252

Herbal medicines

A number of supplements including garlic, ginseng, flavonoids plus herbs are likely to have a role in the prevention and treatment of CVD. Interactions may occur when herbal remedies are utilised with prescription cardiovascular medications, however, CAM used alone specifically to treat cardiovascular conditions is a less common occurrence.253 Therefore it is scientifically plausible that, as the evidence becomes available, an integrative approach to the treatment of CVDs should be adopted.

Hawthorn berries (Crataegus oxycantha)

The herb hawthorn, which is rich in flavonoids, has been shown to have a number of beneficial actions, including coronary vasodilation, protection against ischemia-induced arrhythmia as well as high antioxidant and anti-inflammatory effects.264 Hawthorn has been shown to improve exercise tolerance and decrease the incidence of angina.265 The evidence for hawthorn berries is particularly convincing for the treatment of congestive heart failure according to a recent Cochrane meta-analysis of the literature.266

Red yeast rice extracts (Monascus purpureus)

Red rice has a similar biochemical action to statins where it inhibits HMG CoA reductase and helps to normalise abnormal serum lipids according to a meta-analysis of randomised control trials (RCTs).267 A high dose could cause liver enzyme abnormality similar to statins.47

Red yeast rice extracts have been documented to improve lipid profiles268 and 1 study reported that it was as effective as simvastatin.269 It is interesting to note that simvastatin is also derived from the fungus Aspergillus terreus.

Other heart and vascular diseases

Atrial fibrillation (AF)

Massage therapy

Lymphoedema

Massage therapies such as compression therapy provide a means to treat venous stasis, venous hypertension, and venous oedema. Different methods of compression therapy have been described periodically over the last 2000 years.274 Compression techniques can be static or those utilising specialised compression pumps. The technique of massage called manual lymphatic drainage has emerged to treat primary and secondary lymphoedema.272 Recent reviews have emphasised that there is a need for large controlled trials of the whole range of physical therapies.275

Fish oil supplements

Numerous epidemiological studies, case-control series, and randomised trials have demonstrated the ability of fish oil to reduce major cardiovascular events, particularly sudden cardiac death and all-cause mortality.276 In a study of fish and AF it was demonstrated that in an elderly group of adults, consumption of tuna or other broiled or baked fish, but not fried fish or fish sandwiches, is associated with lower incidence of AF. It was noted that the consumption of fish could influence risk of arrhythmia.277

A review of the evidence suggests fish oils and vitamin C may be useful for the treatment of atrial fibrillation due to their antioxidant and anti-inflammatory qualities by modulating inflammatory pathways.278, 279

A 3-month study randomised 65 obese sedentary volunteers to tuna fish oil supplements (1·56 g/day of DHA and 0·36 g/day of EPA) and compared them to placebo (sunflower oil).280 The fish oil supplement group reduced heart rate variability and significantly attenuated heart rate responses to exercise, and resting heart rate, thereby reducing cardiovascular risk. According to the researchers, the effects are mediated by modulating parasympathetic activity.

A recent systematic review of the literature of 12 studies inclusive of 32 779 patients for fish oils, found most of the studies reported a significant reduction risk for sudden cardiac death, all-cause mortality and a reduction in deaths from cardiac causes that was dose responsive, but interestingly had no effect on arrhythmias or all-cause mortality.281 No conclusion could be drawn from the studies about the optimal formulation of EPA or DHA.

Fish oil supplements can also help regulate heart rate and are recommended for prevention of both atrial and ventricular arrhythmias.246

Alcohol

Alcohol consumption and risk and prognosis of AF among older adults has been reported from the Cardiovascular Health Study.282 Furthermore, recently in patients with CHD, moderate wine drinking was associated with higher marine omega-3 concentrations than no alcohol use. And it was concluded that the effect of wine comparable to that of fish may partly explain the protective effects of wine drinking against CHD.283

Congestive heart failure (CHF)

Obesity

Paradoxically, a cohort of outpatients with established CHF, obese patients with higher BMIs, were associated with lower mortality risks compared with those at a healthy weight.286 All-cause mortality rates increased linearly from 45% in the underweight group to 28.4% in the obese group (P for trend <.001).

Fish oils

A placebo-controlled double-blind trial of up to 7000 patients with symptomatic heart failure from any cause, randomised to omega-3 polyunsaturated fatty acid (PUFA) 1g daily or placebo for a median duration of 3.9 years, found a small but significant reduction in risk of all-cause mortality and cardiovascular hospitalisation.288 The same researchers in a separate study found the statin medication rouvastatin (10mg daily) did not affect the outcome of patients with heart failure.289 Furthermore, there is now strong evidence available that recommends that fish oils should now join the short list of evidence-based life-prolonging therapies for heart failure.290

Fish oil supplementation improved left ventricular function in children with idiopathic dilated cardiomyopathy.291

Magnesium

High levels of magnesium orotate (6g for 1 month, then 3g for 11 months) proved to be an effective adjuvant to medical treatment for patients with severe CHF by improving survival rate and improving quality of symptoms and quality of life.292 Another study demonstrated improved inflammatory marker C-Reactive protein in patients with heart failure after treatment with magnesium 300mg daily compared with standard medical care alone.293

Chinese herb Shengmai

A recent Cochrane review identified 19 trials and found that the Chinese herbs Shengmai plus usual cardiac treatment showed significant improvement in clinical status, reduced risk of mortality, levels of tumour necrosis factor-alpha and improved hemodynanic tests compared to usual treatment alone for heart failure.294 The reporters did note most trials were of poor quality and no adverse affects were reported in any of the trials. They concluded that Shengmai plus usual treatment may be beneficial compared to usual treatment alone for heart failure, but more long-term, high-quality studies are needed.

Conclusion

From the foregoing, and emerging aggregate scientific evidence, the prevention and treatment of CV diseases requires a multi-level intervention. A healthy lifestyle plays an important role in the primary prevention of CHD in middle-aged and older men and women.

The primary objective for health professionals should be to emphasise to the community that CVD can be prevented with lifestyle interventions and within this framework to persuade the community and patients to improve their diets and prudent physical activity and to advise on the safe and cost–effective use of nutritional supplementation when warranted.

One notion that has been advanced is that nutritional supplements cannot be patented, hence the lack of funds for costly clinical trials. This lack of funding most probably explains why it is not conclusively known as to whether reduction of homocysteine can influence CVD, despite the increasing data linking hyper–homocystinemia with CVD. An abstract of a study has demonstrated that multivitamins that contain B group vitamins can significantly reduce blood homocysteine in men at risk for CVD as well as improving depressive symptoms.304

The comprehensive cardio-protective lifestyle and supplementation advice suggested by Lewis17 should be part of routine care of patients by the medical profession.

Many patients need continual reminders, education and support in the importance of lifestyle factors contributing to CVD. Chronic disease self-management education programs are important. The integrative medicine approach must always incorporate the evidence-based use of pharmaceutical therapy. Table 10.3 summarises the level of evidence for some CAM therapies for ASD.

Clinical tips handout for patients with cardiovascular disease

5 Dietary changes

7 Supplements

Vitamins and minerals

Herbal medicines

References

1 World Health Organization—Cardiovascular disease: prevention and control 2003.

2 Australian Bureau of Statistics 3303.0. Causes of death 2006. Released 14 March 2008 http://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/A8CB1F4BD5385085CA2574100010092A/$File/33030_2006.pdf (accessed February 2009)

3 Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723-1727.

4 Ascherio A., Rimm E.B., Giovannucci E.L., et al. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992;86(5):1475-1484.

5 Stevens V.J., Obarzanek E., Cook N.R., et al. Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1-11.

6 Sacks F.M., Bray G.A., Carey V.J., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. NEJM. 2009;360:859-873.

7 Katan M.B. Weight-loss diets for the prevention and treatment of obesity. NEJM. 2009;360:923-924.

8 Heart Foundation. Information for Health Professionals; Reducing Risk in Heart Disease — Full Guidelines. Online. Available: http://www.heartfoundation.org.au/Professional_Information/Clinical_Practice/CHD/Pages/default.aspx (accessed February 2009)

9 Australian and New Zealand Journal of Public Health 2001;25:24–30.

10 Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM. 2002;346:393-403.

11 Akesson A., Weismayer C., Newby P.K., et al. Combined Effect of Low-Risk Dietary and Lifestyle Behaviours in Primary Prevention of Myocardial Infarction in Women. Arch Intern Med. 2007;167(19):2122-2127.

12 Ornish D., Scherwitz L.W., Billings J.H., et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007.

13 Ornish D., Brown S.E., Scherwitz L.W., et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133.

14 Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. AJCN. 83(6 Suppl), 2006. 1505S-1519S

15 Frazao E., Allshouse J. Strategies for intervention: commentary and debate. J Nutr. 2003;133(3):844S-847S.

16 Fairfield K.M., Fletcher R.H. vitamins for chronic disease prevention in adults: scientific review. JAMA. 2002;287(23):3116-3126.

17 Lewis G.R.J. Should doctors discourage nutritional supplementation?: A cardiovascular perspective. Heart Lung Circ. 2004;13(3):245-251.

18 Bibbins-Domingo K, Coxson P, Pletcher MJ et al. Adolescent Overweight and Future Adult Coronary Heart Disease. NEJM 357(23):2371-79

19 Summerbell C.D., Ashton V., Campbell K.J., Edmunds L., Kelly S., Waters E. Interventions for treating obesity in children. Cochrane Database of Systematic Reviews. (Issue 3):2003. Art. No.: CD001872. doi: 10.1002/14651858.CD001872

20 Stuebe A.M., Michels K.B., Willett W.C., et al. Duration of lactation and incidence of myocardial infarction in middle to late adulthood. Am J Obstet Gynecol. 2009;200(2)(138):e1-e8.

21 Kubzansky Laura D., Thurston Rebecca C. Emotional Vitality and Incident Coronary Heart Disease. Benefits of Healthy Psychological Functioning. Arch Gen Psychiatry. 2007;64(12):1393-1401.

22 Nemeroff C.B., Musselman D.L., Evans D.L. Depression and cardiac disease. Depress Anxiety. 1998;8(Suppl 1):71-79. Review

23 Parker G.B., Hilton T.M., Walsh W.F., et al. Timing is everything: the onset of depression and acute coronary syndrome. outcome. Biol Psychiatry. 2008;64(8):660-666.

24 Whooley M.A., de Jonge P., Vittinghoff E., et al. Depressive symptoms, health behaviours, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008;300(20):2379-2388.

25 Kubzansky L.D., Kawachi I., Spiro A.3rd, et al. Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Ageing Study. Circulation. 1997;95:818-824.

26 Mangiafico R.A., Malatino L.S., Attinà T., et al. Exaggerated endothelin release in response to acute mental stress in patients with intermittent claudication. Angiology. 2002;53:383-387.

27 Burg M.M., Barefoot J., Berkman L., et al. Low perceived social support and post-myocardial infarction prognosis in the enhancing recovery in coronary heart disease clinical trial: the effects of treatment. Psychosom Med. 2005;67(6):879-888.

28 Dickens C.M., McGowan L., Percival C., et al. Lack of a close confidant, but not depression, predicts further cardiac events after myocardial infarction. Heart. 2004;90:518-522.

29 Bunker S.J., Colquhoun D.M., et al. Stress’ and coronary heart disease: psychological risk factors. National Heart Foundation of Australia position statement update. MJA. 2003;178:272-276.

30 Friedmann E., Thomas S.A., Stein P.K., Kleiger R.E. Relation between pet ownership and heart rate variability in patients with healed myocardial infarcts. Am J Cardiol. 2003;91:718-721.

31 Fowler James H., Christakis Nicholas A. Dynamic spread of happiness in a large social network: longitudinal analysis over 20 years in the Framingham Heart Study. BMJ. 2008;337:a2338.

32 Orth-Gomér K., Wamala S.P., Horsten M., et al. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA. 2000;284:3008-3014.

33 Rohrbaugh M.J., Shoham V., Coyne J.C. Effect of marital quality on eight-year survival of patients with heart failure. Am J Card. 2006;98:1069-1072.

34 De Vogli R., Chandola T., Marmot M.G. Negative aspects of close relationships and heart disease. Arch Int Med. 2007;167:1951-1957.

35 Rohrbaugh M.J., Shoham V., Coyne J.C. Effect of marital quality on eight-year survival of patients with heart failure. Am J Card. 2006;98(8):1069-1072.

36 Napadow V., Ahn A., Longhurst J., et al. The status and future of acupuncture clinical research. J Altern Complement Med. 2008;14(7):861-869.

37 Artinian N.T., Washington O.G., Flack J.M., et al. Depression, stress, and blood pressure in urban African-American women. Prog Cardiovasc Nurs. 2006;Spring;21(2):68-75.

38 Wilbert-Lampen U., Leistner D., Greven S., et al. Cardiovascular Events during World Cup Soccer. NEJMe. 2008;358(5):475-483.

39 Wittstein I.S., Thiemann D.R., Lima J A., et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. NEJM. 2005;352:539-548.

40 Connelly K.A., MacIsaac A.I., Jelinek V.M. Stress, myocardial infarction, and the ‘tako-tsubo’ phenomenon. Heart. 2004;90:e52.

41 Vitetta L., Anton B., Cortizo F., Sali A. Mind-body medicine: stress and its impact on overall health and longevity. Ann N Y Acad Sci. 2005;1057:492-505.

42 Surtees P.G., Wainwright N.W., Luben R.N., et al. Psychological distress, major depressive disorder, and risk of stroke. Neurology. 2008;70:788-794.

43 Wang H.X., Leineweber C., Kirkeeide R., et al. Psychosocial stress and atherosclerosis: family and work stress accelerate progression of coronary disease in women. The Stockholm Female Coronary Angiography Study. J Intern Med. 2007;261:245-254.

44 Brotman D.J., Golden S.H., Wittstein I.S. The cardiovascular toll of stress. Lancet. 2007;370:1089-1100.

45 Aboa-Eboulé C., Brisson C., Maunsell E., et al. Job strain and risk of acute recurrent coronary heart disease events. JAMA. 2007;298:1652-1660.

46 Kivimäki M., Ferrie J.E., Brunner E., et al. Justice at work and reduced risk of coronary heart disease among employees: the Whitehall II Study. Arch Int Med. 2005;165:2245-2251.

47 Marmot M.G., Bosma H., Hemingway H., Brunner E., Stansfeld S. Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet. 1997;350:235-239.

48 Matthews K.A., Gump B.B., Harris K.F., et al. Hostile behaviours predict cardiovascular mortality among men enrolled in the Multiple Risk Factor Intervention Trial. Circulation. 2004;109:66-70.

49 Williams J.E., Nieto F.J., Sanford C.P., Tyroler H.A. Effects of an angry temperament on coronary heart disease risk: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2001;154:230-235.

50 Eaker E.D., Sullivan L.M., Kelly-Hayes M., et al. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation. 2004;109:1267-1271.

51 Castillo-Richmond A., Schneider R.H., Alexander C.N., Cook R., Myers H., Nidich S., Haney C., Rainforth M., Salerno J. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke. 2000;31(3):568-573.

52 Blumenthal J.A., Jiang W., Babyak M.A., et al. Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. Arch Int Med. 1997;157:2213-2223.

53 Bernardi L., Porta C., Sleight P. Cardiovascular, cerebrovascular, and respiratory changes induced by different types of music in musicians and non-musicians: the importance of silence. Heart. 2006;92(4):445-452.

54 Naska A., Oikonomou E., Trichopoulou A., et al. Siesta in Healthy Adults and Coronary Mortality in the General Population. Arch Intern Med. 2007;167:296-301.

55 Empana J.P., Dauvilliers Y., Dartigues J.F., et al. Excessive Daytime Sleepiness Is an Independent Risk Indicator for Cardiovascular Mortality in Community-Dwelling Elderly. The 3 City Study. Stroke. 2009 Feb 26. (Epub ahead of print)

56 King C.R., Knutson K.L., Rathouz P.J., Sidney S., Liu K., Lauderdale D.S. Short sleep duration and incident coronary artery calcification. JAMA. 2008;300(24):2859-2866.

57 Eguchi K., Pickering T.G., Schwartz J.E., et al. Short Sleep Duration as an Independent Predictor of Cardiovascular Events in Japanese Patients With Hypertension. Arch Intern Med. 2008;168(20):2225-2231.

58 Cohen M.C., Rohtla K.M., Lavery C.E., Muller J.E., Mittleman M.A. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol. 1997;79(11):1512-1516.

59 Marin J.M., Carrizo S.J., Vicente E., Agusti A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046-1053.

60 Gami A.S., et al. Day-night pattern of sudden death in obstructive sleep apnea. NEJM. 2005;352:1206-1214.

61 Lee S.A., Amis T.C., Byth K., Larcos G., Kairaitis K., Robinson T.D., Wheatley J.R. Heavy snoring as a cause of carotid artery atherosclerosis. Sleep. 2008;31(9):1207-1213.

62 Michos E.D., Melamed M.L. vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008;11(1):7-12.

63 Zitterman A., Schleithoff S.S., Koerfer R. Putting cardiovascular diseases and vitamin D insufficiency into perspective. Br J Nutr. 2005;94:483-492.

64 Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension1997;30(2.1):150-56

65 Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6):1678S-1688S.

66 Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure (letter). Lancet. 1998;352:709-710.

67 Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int. J Epidemiol. 1981;10(4):337-341.

68 Grant W.B., Strange R.C., Garland C.F. Sunshine is good medicine. The health benefits of ultraviolet-B induced vitamin D production. J Cosmet Dermatol. 2003;2(2):86-98.

69 Heaney R.P. Nutrition and Chronic Disease. Mayo Clinic Proceedings. March 2006;81(3):297-299.

70 Grant W.B., Holick M.F. Benefits and requirements of vitamin D for optimal health: a review. Alter Med Rev. 2005;10:94-111.

71 Holick M.F. The vitamin D Epidemic and its Health Consequences. J Nutr. 2005;135:2739S-2748S.

72 Lee J.H., O’Keefe J.H., Bell D., Hensrud D.D., Holick M.F. vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949-1956.

73 Autier P., Gandini S. vitamin D Supplementation and Total Mortality.A Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2007;167(16):1730-1737.

74 Melamed M.L., Muntner P., Michos E.D., et al. Serum 25-Hydroxyvitamin D levels and the prevalence of peripheral arterial disease. Results form NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol. 2008 Apr 16. Epub ahead of print

75 Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. AJCN. 2004;80(6 Suppl):1678S-1688S.

76 Holick M.F. vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J. 2005;98(10):1024-1027.

77 Dobnig H., Pilz S., Scharnagl H., Renner W., et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349.

78 Zittermann A. vitamin D and disease prevention with special reference to cardiovascular disease. Progress of Biophysics and Molecular Biology. 2006;82:39-48.

79 Fahrleitner A., Dobnig H., Obernosterer A., et al. vitamin D deficiency and secondary hyperparathyroidism are common complications inpatients with peripheral arterial disease. J Gen Intern Med. 2002;17:663-669.

80 Levin A., Li Y.C. vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005;68(5):1973-1981.

81 Sepulveda J.L., Mehta J.L. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opinion Cardiol. 2005;20:407-416.

82 Schmidt-Gayk H., Goossen J., Lendle F., Seidel D. Serum 25-hydroxycholecalciferol in myocardial infarction. Atherosclerosis. 1977;26:55-58.

83 Scragg R., Jackson R., Holdaway J.M., Lim T., Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990;19(3):559-563.

84 Zitterman A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-112.

85 Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Internal Medicine. 2008;168:1340-1349.

86 Pekkanen J., Peters A., Hoek G., et al. Particulate air pollution and risk of ST-segment depression during repeated submaximal exercise tests among subjects with coronary heart disease: the Exposure and Risk Assessment for Fine and Ultrafine Particles in Ambient Air (ULTRA) study. Circulation. 2002;106(8):933-938.

87 Miller K.A., Siscovick D.S., Sheppard L., et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. NEJM. 2007;356:447-458.

88 Dockery D.W., Stone P.H. Cardiovascular risks from fine particulate air pollution. NEJM. 2007;356:511-513.

89 Peters A., von Klot S., Heier M., et al. Exposure to traffic and the onset of myocardial infarction. NEJM. 2004;351:1721-1730.

90 Stone P.H. Triggering myocardial infarction. NEJM. 2004;351:1716-1718.

91 Brooke R.D. Air Pollution: What Is Bad for the Arteries Might Be Bad for the Veins. Arch Int Med. 2008;168:909-911.

92 Mills N.L., Törnqvist H., Gonzalez M.C., et al. Ischemic and Thrombotic Effects of Dilute Diesel-Exhaust Inhalation in Men with Coronary Heart Disease. NEJM. 2007;357:1075-1082.

93 Kenfield S.A., et al. Smoking and smoking cessation in relation to mortality in women. JAMA. 2008;299:2037-2047.

94 Hurley Susan F. Short-term impact of smoking cessation on myocardial infarction and stroke hospitalisations and costs in Australia. MJA. 2005;183:13-17.

95 US Department of Health and Human Services. Physical activity and health: A report of the Surgeon General. Atlanta: Centre for Disease Control and Prevention; 1996. Online. Available: www.cdc.gov (accessed 10 March 2009)

96 Gordon-Larsen P, Hou N, Sidney S et al. Fifteen-year longitudinal trends in walking patterns and their impact on weight change. AJCN 200989:19-26

97 Briffa T.G., Maiorana A., Sheerin N.J., et al. Physical activity for people with cardiovascular disease: recommendations of the National Heart Foundation of Australia. MJA. 2006;184(2):71-75.

98 Lett H.S., Davidson J., Blumenthal J.A. Nonpharmacologic treatments for depression in patients with coronary heart disease. Psychosom Med. 2005;67(Suppl. 1):S58-S62.

99 Jayasinghe S.R. Yoga in cardiac health (a review). Eur J Cardiovasc Prev Rehabil. 2004;11(5):369-375.

100 Nazzaro P., Triggiani R., Ciancio L., et al. Insulin resistance in essential hypertension: a psychophysiological approach to the ‘chicken and egg’ question. Nutr Metab Cardiovasc Dis. 2000;10(5):275-286.

101 Schneider R.H., Alexander C.N., Salerno J.W., et al. Disease prevention and health promotion in the ageing with a traditional system of natural medicine: Maharishi Vedic Medicine. J Ageing Health. 2002;14(1):57-78.

102 King M.S., Carr T., D’Cruz C. Transcendental meditation, hypertension and heart disease. Aust Fam Phys. 2002;31(2):164-168.

103 Fields J.Z., Walton K.G., et al Schneider R.H. Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of Maharishi Vedic Medicine. Am J Cardiol. 2002;89(8):952-958.

104 Innes K.E., Vincent H.K., Taylor A.G. Chronic stress and insulin resistance-related indices of cardiovascular disease risk, part 2: a potential role for mind-body therapies. Altern Ther Health Med. 2007;13(5):44-51.

105 Manchanda S.C., Narang R., Reddy K.S., et al. Retardation of coronary atherosclerosis with yoga lifestyle intervention. J Assoc Physicians India. 2000;48(7):687-694.

106 Hong Y., Li J.X., Robinson P.D. Balance control, flexibility, and cardiorespiratory fitness among older Tai Chi practitioners. Br J Sports Med. 2000;34:29-34.

107 Rogers C.E., Larkey L.K., Keller C. A review of clinical trials of tai chi and qigong in older adults. West J Nurs Res. 2009;31(2):245-279.

108 Lee M.S., Pittler M.H., Guo R., Ernst E. Qigong for hypertension: A systematic review of randomized clinical trials. Journal of Hypertension. 2007;25(8):1525-1532.

109 Yang Y., Verkuilen J.V., Rosengren K.S., Grubisich, et al. Effect of combined taiji and qigong training on balance mechanisms: A randomized controlled trial of older adults. Medical Science Monitor. 2007;13(8):CR339-CR348.

110 Tsang H.W.H., Fung K.M.T., Chan ASM et al. Effect of a qigong exercise program on elderly with depression. International J Geriat Psych. 2006;21(9):890-897.

111 Sancier K.M. Therapeutic benefits of qigong exercises in combination with drugs. J Alter Complem Med 1999. 1999;5(4):383-389.

112 Arthur H.M., Patterson C., Stone J.A. The role of complementary and alternative therapies in cardiac rehabilitation: a systematic evaluation. Eur J Cardiovasc Prev Rehab. 2006;13(1):3-9.

113 Lee M.J., Kilbreath S.L., Singh M.F., et al. Comparison of effect of aerobic cycle training and progressive resistance training on walking ability after stroke: a randomized sham exercise-controlled study. J Am Geriatr Soc. 2008;56(6):976-985.

114 Westhoff T.H., Schmidt S., Gross V., et al. The cardiovascular effects of upper-limb aerobic exercise in hypertensive patients. J Hypertens. 2008;26(7):1336-1342.

115 Smith F.W.Jr. Acupuncture for cardiovascular disorders. Probl Vet Med. 1992;4(1):125-131.

116 VanWormer A.M., Lindquist R., Sendelbach S.E. The effects of acupuncture on cardiac arrhythmias: a literature review. Heart Lung. 2008;37(6):425-431.

117 Ginter E. Vegetarian diets, chronic diseases and longevity. Bratisl Lek Listy. 2008;109(10):463-466.

118 Iqbal R., Anand S., Ounpuu S., et al. on behalf of the INTERHEART Study Investigators. Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries. Results of the INTERHEART Study. Circulation. 2008;118:1929-1937.

119 Berg C.M., Lappas G., Strandhagen E., et al. Food patterns and cardiovascular disease risk factors: The Swedish INTERGENE research program. AJC N. 2008;88:289-297.

120 Brunner E.J., Rees K., Ward K., Burke M., Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database of Systematic Reviews. (Issue 4):2007. Art. No.: CD002128. doi: 10.1002/14651858.CD002128.pub3

121 Keys A. Mediterranean diet and public health: personal reflections. AJCN. 1995;61(6 Suppl):1321S-1323S.

122 Costacou T., Edmundowicz D., et al. Progression of coronary artery calcium in type 1 diabetes mellitus. 2007;100(10):1543-1547.

123 Rosemary Stanton. Australian Doctor 30 January 2009:29–30.

124 Nakamura Kozue, Nagata Chisato, Oba Shino, Takatsuka Naoyoshi, Shimizu Hiroyuki. Fruit and Vegetable Intake and Mortality from Cardiovascular Disease Are Inversely Associated in Japanese Women but Not in Men. J Nutr. 2008;138:1129-1134.

125 Jarrett P.G., Rockwood K., Carver D., et al. Illness presentation in elderly patients. Arch Intern Med. 2007;167:1060-1067.

126 Fung T.T., Rexrode K.M., Mantzoros C.S., et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation. 2009;119(8):1093-1100.

127 SOLOS (Spanish Olive Oil Study) Study Investigators. Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: a randomized, cross-over, controlled trial. Eur J Clin Nutr. 2008;62:570-574. doi:10.1038/sj.ejcn.1602724

128 Franco O.H., Bonneux L., de Laet C., et al. The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ. 2004;329:18-25.

129 Sofi F., et al. Adherence to Mediterranean diet and health status: a meta-analysis. B MJ. 2008;337:a1344.

130 Martínez-González M.A., de la Fuente-Arrillaga C., Nunez-Cordoba J.M., et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ. 2008;336(7657):1348-1351.

131 Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. NEJM. 1997;336(16):1117-1124.

132 Ascherio A., Rimm E.B., Giovannucci E.L., et al. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992;86(5):1475-1484.

133 Fung T.T., Chiuve S.E., McCullough M.L., et al. Adherence to a DASH-Style Diet and Risk of Coronary Heart Disease and Stroke in Women Archives of Internal Medicine. 2008;168(7):713-720.

134 Pereira M.A., O’Reilly E., Augustsson K., et al. Dietary fibre and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med. 2004;164(4):370-376.

135 Djoussé L., Gaziano M.J. Breakfast Cereals and Risk of Heart Failure in the Physicians’ Health Study I. Arch Intern Med. 2007;167(19):2080-2085.

136 Erkkilä A.T., Herrington D.M., Mozaffarian D., Lichtenstein A.H. Cereal fibre and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in post-menopausal women with coronary artery disease. Am Heart J. 2005;150:94-101.

137 Andon M.B., Anderson J.W. State of the Art Reviews: The Oatmeal-Cholesterol Connection: 10 Years Later. Am J Lifestyle Med. 2008;2(1):51-57.

138 Vincent-Baudry S., Defoort D., Gerber M., et al. The Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet. AJCN. 2005;82:964-971.

139 Segasothy M., Phillips P.A. Vegetarian diet: panacea for modern lifestyle diseases? QJM. 1999;92(9):531-544.

140 Howard B.V., Van Horn L., Hsia J., et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):655-666.

141 Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885-1899.

142 Iso H., Kobayashi M., et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation. 2006;113(2):195-202.

143 Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274:1363-1367.

144 Mozaffarian D., Bryson C.L., Lemaitre R.N., Burke G.L., Siscovick D.S. Fish intake and risk of heart failure. J Am Coll Cardiol. 2005;45:2015-2021.

145 Mozaffarian D., Psaty B.M., Rimm E.B., et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110:368-373.

146 Ros E., Núñez I., Pérez-Heras A., Serra M., et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized cross-over trial. Circulation. 2004;109:1609-1614.

147 Gillen L.J., Tapsell L.C., Patch C.S., et al. Structured dietary advice incorporating walnuts achieves optimal fat and energy balance in patients with type 2 diabetes mellitus. J Am Dietet Assoc. 2005;105:1087-1095.

148 Gebauer S.K., West S.G., Kay C.D., et al. Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: a dose-response study. AJCN. 2008;88(3):651-659.

149 Phillips K.M., Ruggio D.M., Ashraf-Khorassani M. Phytosterol composition of nuts and seeds commonly consumed in the United States. J Agric Food Chem. 2005;53:9436-9445.

150 Vermeer C., Shearer M.J., Zittermann A., et al. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004;43(6):325-335.

151 Berkner K.L., Runge K.W. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004;2(12):2118-2132.

152 Geleijnse J.M., Vermeer C., Grobbee D.E., et al. Dietary intake of menaquinone is associated with a reduced risk of coronoary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-3105.

153 Schurgers L.J., Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 2000;30(6):298-307.

154 Cook N.R., Cutler J.A., Obarzanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885.

155 Dickinson K.M., Keogh J.B., Clifton P.M. Effects of a low-salt diet on flow-mediated dilatation in humans. Am J Clin Nutr. 2009 Feb;89(2):485-490.

156 Lee R., Balick M. Rx: chocolate. Explore (NY). 2005;1(2):136-139.

157 di Giuseppe R., Di Castelnuovo A., Centritto F., Zito F., De Curtis A., Costanzo S., Vohnout B., Sieri S., Krogh V., Donati M.B., de Gaetano G., Iacoviello L. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy italian population. J Nutr. 2008;138:1939-1945.

158 Balzer J., Rassaf T., Heiss C., et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J Am Coll Cardiol. 2008;551:2141-2149.

159 Engler M.B., Engler M.M., Chen C.Y., et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr. 2004;23:197-204.

160 Britton A., Marmot M.G., Shipley M. Who benefits most from the cardio-protective properties of alcohol consumption—health freaks or couch potatoes? Journal of Epidemiology and Community Health. 2008;62:905-908.

161 Mukamal K.J., Chiuve S.E., Rimm E.B. Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. Arch Intern Med. 2006;166:2145-2150.

162 de Lorimier A.A. Alcohol, wine, and health. Am J Surgg. 2000;180(5):357-361.

163 Bertelli A.A. Wine, research and cardiovascular disease: instructions for use. Atherosclerosis. 2007;195:242-247.

164 Kuriyama S., et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006;296:1255-1265.

165 Gardner E.J., Ruxton C.H., Leeds A.R. Black tea–helpful or harmful? A review of the evidence. Eur J Clin Nutr. 2007;61(1):3-18.

166 Berger Adam J., Alford Kevin. Cardiac arrest in a young man following excess consumption of caffeinated ‘energy drinks’. MJA. 2009;190:41-43.

167 Namdar M., Koepfli P., Grathwohl R., et al. Caffeine decreases exercise-induced myocardial flow reserve. J Am Coll Cardiol. 2006;47:405-410.

168 Lopez-Garcia E., van Dam R.M., Willett W.C., et al. Coffee consumption and coronary heart disease in men and women: a prospective cohort study. Circulation. 2006;113:2045-2053.

169 Silletta M.G., Marfisi R., Levantesi G., et al. Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico)-Prevenzione trial. Circulation. 2007;116(25):2944-2951.

170 Sumner M.D., Elliott-Eller M., Weidner G., et al. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Amer J Cardiol. 2005;96:810-814.

171 Houston M.C., Cooil B., Olafsson B.J., Raggi P. Juice Powder Concentrate and Systemic Blood Pressure, Progression of Coronary Artery Calcium and Antioxidant Status in Hypertensive Subjects: A Pilot Study. Evid Based Complement Alternat Med. 2007;4(4):455-462.

172 Block Gladys, Jensen Christopher D., Norkus Edward P., Dalvi Tapashi B., Wong Les G., McManus Jamie F., Hudes Mark L. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutrition Journal. 2007;6:30. doi:10.1186/1475-2891-6-30

173 Hercberg S., Galan P., Preziosi P., Bertrais S., Mennen L., Malvy D., Roussel A.M., Favier A., Briançon S. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164(21):2335-2342.

174 Palinski W., Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Int Med. 2000;247(3):371-380.

175 Engler M.M., Engler M.B., Malloy M.J., et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003;108(9):1059-1063. 272

176 Blumberg J.B. An update: vitamin E supplementation and heart disease. Nutr Clin Care. 2002;5(2):50-55. 274

177 Munteanu A., Zingg J.M., Azzi A. Anti-atherosclerotic effects of vitamin E—myth or reality? J Cell Mol Med. 2004;8(1):59-76. 277

178 Colquhoun D.M. Nutraceuticals: vitamins and other nutrients in coronary heart disease (Review). Curr Opin Lipidol. 2001;12(6):639-646. 280

179 Celestini A., Pulcinelli F.M., Pignatelli P., et al. vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. Haematologica. 2002;87(4):420-426.

180 Hamabe A., Takase B., Uehata A., et al. Impaired endothelium-dependent vasodilation in the brachial artery in variant angina pectoris and the effect of intravenous administration of vitamin C. Am J Cardiol. 2001;87(10):1154-1159.

181 Sesso H.D., Buring J.E., Christen W.G., et al. vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300:2123-2133.

182 Cook N.R., Albert C.M., Gaziano M.J., et al. A Randomized Factorial Trial of vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women. Results From the Women’s Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167(15):1610-1618.

183 Sali A., Vitetta L. Nutritional supplements and cardiovascular disease. Heart Lung Circ. 2004;13(4):363-366.

184 Goldberg A.C. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol. 2004;94(1):121-124.

185 Aleman G., Tovar A.R., Torres N. Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12. Rev Invest Clin. 2001;53(2):141-151.

186 Kolling K., Ndrepepa G., Koch W., et al. Methylenetetrahy-drofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol. 2004;93(10):1201-1206.

187 Hickling S., Hung J., Knuiman M., et al. Impact of voluntary folate fortification on plasma homocysteine and serum folate in Australia from 1995 to 2001. a population based cohort study J Epid Comm Health. 2005;59:371-376.

188 Quadri P., Fragiacomo C., Pezzati R., et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. AJCN. 2004;80(1):114-122.

189 Oakley G.P.Jr. Global prevention of all folic acid-preventable spina bifida and anencephaly by 2010. Community Genet. 2002;5(1):70-77.

190 Bailey L.B., Rampersaud G.C., Kauwell G.P. Folic acid supplements and fortification affect the risk for neural tube defects, vascular disease and cancer: evolving science (Review). J Nutr. 2003;133(6):1961S-1968S.

191 Ferguson L.R., Philpott M., Karunasinghe N. Dietary cancer and prevention using antimutagens. Toxicology. 2004;198(1–3):147-159.

192 Martinez M.E., Henning S.M., Alberts D.S. Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. AJCN. 2004;79(4):691-697.

193 Zhang S.M., Willett W.C., Selhub J., et al. A prospective study 317of plasma total cysteine and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt 1):1188-1193. 319

194 Albert C.M., Cook N.R., Gaziano J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027-2036.

195 Ebbing M., Bleie Ø, Ueland P.M., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300(7):795-804.

196 Li Y.C. vitamin D regulation of the rennin-angiotensin system. J Cell Biochem. 2003;88:327-331.

197 Sepulveda J.L., Mehta J.L. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opinion Cardiol. 2005;20:407-416.

198 McCarty M.F. Secondary hyperparathyroidism promotes the acute phase response-a rationale for supplemental vitamin D in the prevention of vascular events in the elderly. Med Hypotheses. 2005;64:1022-1026.

199 Vermeer C., Braam L., Knapen M., Schurgers L. vitamin K supplementation: a simple way to improve vascular health. Agr Food Industry Hi Tech. Nov 2003.

200 Braam LAJLM. Thesis, Maastricht ISBN 90-5681-145-2, 2002.

201 Spronk H.M., Soute B.A., Schurgers L.J., et al. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res. 2003;40(6):531-537.

202 Kawashima H., Nakajima Y., Matubara Y., et al. Effects of vitamin K2 (menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits. Jpn J Pharmacol. 1997;75(2):135-143.

203 Sconce E., Khan T., Mason J., et al. Patients with unstable control have a poor dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005;93(5):872-875.

204 Sconce E., Khan T., Mason J., et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005;93(5):872-875.

205 Couris R., Tataronis G., McCloskey W., et al. Dietary vitamin K variability affects International Normalized Ration (INR) coagulation indices. Int J vitamin Nutr Res. 2006;76(2):65-74.

206 Sconce E., Avery P., Wynne H., Kamali F. vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007;109(6):2419-2423.

207 Khan T., Wynne H., Wood P., et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol. 2004;124(3):348-354.

208 Turlapaty P.D., Altura B.M. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science. 1980;208(4440):198-200.

209 Altura B.M. Ischemic heart disease and magnesium (Review). Magnesium. 1988;7(2):57-67.

210 Schecter M., Shahir M., Labrador M.J., et al. Oral magnesium therapy improves endothelial function, in patients with coronary artery disease. Circulation. 2000;102(19):2353-2358.

211 Schecter M., et al. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol. 2003;91(5):517-521.

212 Leone N., Courbon D., Ducimetiere P., Zureik M. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology. 2006 May;17(3):308-314.

213 Tejada T., Fornoni A., Lenz O., Materson B.J. Nonpharmacologic therapy for hypertension: does it really work? Curr Cardiol Rep. 2006;8(6):418-424. Review

214 Jee S.H., Miller E.R.3rd, Guallar E., et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized control trials. Am J Hypertens. 2002;15(8):691-696.

215 Teo K.K., Yusuf S. Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. Drugs. 1993;46(3):347-359.

216 Thogersen A.M., Johnson O., Wester P.O. Effects of intravenous magnesium sulfate in suspected acute myocardial infarction on acute arrhythmias and long-term outcome. Int J Cardiol. 1995;49(2):143-151.

217 Shechter M., Kaplinsky E., Rabinowitz B. The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature. Arch Intern Med. 1992;152(11):2189-2196.

218 Fourth International Study of Infarct Survival Collaboration Group. ISIS-4: A randomized factorial trial assessing oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.

219 ISIS-4 (Fourth International Study of Infarct Survival) Collaboration Group. ISIS-4: A randomized factorial trial assessing oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.

220 The Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomized controlled trial. Lancet. 2002;360:1189-1196.

221 Bolland M.J., Barber P.A., Doughty R.N., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ, doi:10.1136/bmj.39440.525752.BE. 15 January 2008.

222 Kardinaal A.F., Kok F.J., Kohlmeier L., Martin-Moreno J.M., et al. Association between toenail selenium and risk of acute myocardial infarction in European men. The EURAMIC Study. European Antioxidant Myocardial Infarction and Breast Cancer. Am J Epidemiol. 1997;145(4)(347):373-379.

223 Rayman M.P. The importance of selenium to human health. Lancet. 2000;356(9225):233-241.

224 Thomson C.D. Selenium and iodine intakes and status in New Zealand and Australia. Br J Nutr. 91(5), 2004. 661–352

225 Li H., Stampfer M.J., Giovannucci E.L., et al. A prospective study of plasma selenium levels and prostate cancer risk. JNCI. 2004;96(9):696-703.

226 Mozaffarian D., Greelen A., Brouwer I.A., et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. 2005;112:1945-1952.

227 O’Keefe J.H.Jr., Abuissa H., Sastre A., et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97:1127-1130.

228 Ninio D.M., Hill A.M., Howe P.R., et al. Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults. Br J Nutr. 2008;100(5):1097-1103.

229 Mozaffarian D., Geelen A., Brouwer I.A., et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials Ciculation. 2005;112:1945-1952.

230 Kris-Etherton P.M., Harris W.S., Appel L.J., et al. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association (Review). Arterioscler Thromb Vasc Biol. 2003;23(2):151-152.

231 Kris-Etherton P.M., HarrisWS, Appel L.J., et al. American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-2757.

232 Harris W.S., Mozaffarian D., Rimm E., et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 2009;119(6):902-907.

233 Colquhoun DFerreira A., Udell T, Eden B. APD, and the Nutrition and Metabolism Committee of the Heart Foundation. Review of evidence: Fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health. Position statement on fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health (updated November 2008). Heart Foundation. Online. Available: http://www.heartfoundation.org.au/Healthy_Living/Eating_and_Drinking/Fish/Pages/default.aspxhttp, http://www.heartfoundation.org.au/SiteCollectionDocuments/HW_FS_FishOils_PS_FINAL_web.pdfPosition Statement references, Position Statement references: http://www.heartfoundation.org.au/SiteCollectionDocuments/HW_FS_FishOil_PS_References_FINAL.pdf (accessed 01-02-09)

234 Anand R.G., Alkadri M., Lavie C.J., Milani R.V. The role of fish oil in arrhythmia prevention. J Cardiopul Rehabil Prev. 2008;28(2):92-98.

235 GISSI—P trial Authors. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447-455.

236 Woodman R.J., Mori T.A., Burke V., et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis. 2003;166(1):85-93.

237 Bhagavan H. Chopra N&R. Potential role of ubiquinone (Co Enzyme Q10) in pediatric cardiomyopathy. Clin Nutr. 2005;24(3):331-338.

238 Gaby A.R. The role of coenzyme Q10 in clinical medicine:part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Alt Med Rev. 1996;1:168-175.

239 Thomas S.R., Whiting P.K., Stocker R. A role of reduced Co Enzyme Q10 in atherosclerosis? Biofactors. 1999;9:207-224.

240 Rosenfelt Frank. Editorial. CoEnzyme Q10 therapy for cardiac disease: science of alternative medicine? Asia Pacific Heart J. 1998;7(3):160-168.

241 Kuettner A., Pieper A., Koch J., et al. Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study. Int J Cardiol. 2005;98(3):413-419.

242 Tiano L., Belardinelli R., Carnevali P., et al. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 2007;28(18):2249-2255.

243 Kamikawa T., Kobayashi A., Yamashita T., et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pertoris. Am J Cardiol. 1985;56(4):247-251.

244 Rundek T., Naini A., Sacco R., Coates K., Di Mauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk of cardiovascular disease and stroke. Arch Neurol. 2004;61(6):889-892.

245 Dyck J.R., Hopkins T.A., Bonnet S., et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation. 2006;114:1721-1728.

246 Arduini A., Bonomini M., Savica V., et al. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther. 2008;120(2):149-156.

247 Vescovo G., Ravara B., Gobbo V., et al. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol. 2002;283(3):C802-C810.

248 Davini P., Bigalli A., Lamanna F., Boem A. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18:355-365.

249 Iliceto S., Scrutinio D., Bruzzi P., et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: The L-carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26:380-387.

250 Tarantini G., Scrutinio D., Bruzzi P., et al. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology. 2006;106:215-223.

251 Demeyere R., Lormans P., Weidler B., et al. Cardio-protective effects of carnitine in extensive aortocoronary bypass grafting: A double-blind, randomized, placebo-controlled clinical trial. Anesth Analg. 1990;71:520-528.

252 Malaguarnera M., Cammalleri L., Gargante M.P., et al. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr. 2007;86(6):1738-1744.

253 Yeh G.Y., Davis R.B., Phillips R.S. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006;98(5):673-680.

254 Koscielny J., Klussendorf D., Latza R., et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis. 1999;144(1):237-249.

255 Banerjee S.K., Maulik S.K. Effect of garlic on cardiovascular disorders: a review. Nutr Jour. 2002;1(4):1-14.

256 Bongiorno P.B., Fratellone P.M., LoGiudice P. ‘Potential Health Benefits of Garlic (Allium sativum). A Narrative Review,’ Journal of Complementary and Integrative Medicine. 5(1), 2008. http://www.bepress.com/jcim/vol5/iss1/1/ (accessed February 2009)

257 Breithaupt-Groegler K., Ling M., Boudoulas H., Belz G.G. Protective effect of chronic garlic intake on elastic properties of aorta in the elderly. Circulation. 1997;96:2649-2655.

258 van Doorn M.B., Espirito Santo S.M., Meijer P., Kamerling I.M., Schoemaker R.C., Dirsch V., Vollmar A., Haffner T., Gebhardt R., Cohen A.F., Princen H.M., Burggraaf J. Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects. AJ CN. 2006;84(6):1324-1329.

259 Gardner C.D., Lawson L.D., Block E., et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med. 2007;167(4):346-353.

260 Allison G.L., Lowe G.M., Rahman K. Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. J Nutr. 2006;136(3 Suppl):782S-788S.

261 Der Marderosian A., editor. The review of natural products. Facts and comparisons. Philadelphia: Lippincott, Williams and Wilkins, 2001.

262 Patel A.K., Rogers J.T., Huang X. Flavanols, mild cognitive impairment, and Alzheimer’s dementia. Int J Clin Exp Med. 2008;1(2):181-191.

263 Joseph J.A., Shukitt-Hale B., Denisova N.A., et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioural deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci. 1999;19(18):8114-8121.

264 Kendler B.S. Recent nutritional approaches to the prevention and therapy of cardiovascular disease (Review). Prog Cardiovasc Nurs. 1997;Summer 12(3):3-23.

265 Weng W.L., Zhang W.Q., Liu F.Z., et al. Therapeutic effect of Crataegus pinnatifida on 46 cases of angina pectoris—a double-blind study. J Tradit Chin Med. 1984;4(4):293-294.

266 Pittler M.H., Guo R., Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database of Systematic Reviews. (Issue 1):2008. Art. No.: CD005312. doi: 10.1002/14651858.CD005312.pub2

267 Liu J., Zhang J., Shi Y., et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.

268 Heber D., Yip I., Ashley J.M., et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. AJCN. 1999;69(2):231-236.

269 Kou W., Lu Z., Guo J. Effect of xuezhikang on the treatment of primary hyperlipidemia. Zhonghua Nei Ke Za Zhi. 1997;36(8):529-531.

270 Duan X., Zhou L., Wu T., Liu G., et al. Chinese herbal medicine suxiao jiuxin wan for angina pectoris. Cochrane Database of Systematic Reviews. (1):2008.

271 Mozaffarian D., Furberg C.D., Patsy B.M., Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008;118(8):800-807.

272 Felty C.L., Rooke T.W. Compression therapy for chronic venous insufficiency. Semin Vasc Surg. 2005 Mar;18(1):36-40.

273 Badger C., Preston N., Seers K., Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. (4):2004 Oct 18. CD003141

274 Anand R.G., Alkadri M., Lavie C.J., Milani R.V. The role of fish oil in arrhythmia prevention. J Cardiopul Rehabil Prev. 2008;28(2):92-98.

275 Mozaffarian D., Psaty B.M., Rimm E.B., et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110(4):368-373.

276 Boos C.J., Anderson R.A., Lip G.Y.H. Is atrial fibrillation an inflammatory disorder? European Heart Journal. 2005;27(2):136-149.

277 Korantzopoulos P., Kolettis T.M., Galaris D., Goudevenos J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Intern J Cardiol. 2007;115(2):135-143.

278 Ninio D.M., Hill A.M., Howe P.R., et al. Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults. Br J Nutr. 2008;100(5):1097-1103.

279 Hernando Leo’n, Shibata Marcelo C., Dorgan Marlene, Tsuyuki Ross T. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2009;338:a2931. doi:10.1136/bmj.a2931

280 Mukamal K.J., Psaty B.M., Rautaharju P.M., et al. Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. Am Heart J. 2007;153(2):260-266.

281 de Lorgeril M., Salen P., Martin J.L., et al. Interactions of wine drinking with omega-3 fatty acids in patients with coronary heart disease: a fish-like effect of moderate wine drinking. Am Heart J. 2008;155(1):175-181.

282 Davey M.J., Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Emerg Med. 2005;45:347-353.

283 Pittler M.H., Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database of Systematic Reviews. (Issue 1):2006. Art. No.: CD003230. doi: 10.1002/14651858.CD003230.pub3

284 Curtis J.P., Selter J.G., Wang Y., et al. The Obesity Paradox. Body Mass Index and Outcomes in Patients With Heart Failure. Arch Intern Med. 2005;165:55-61.

285 Mozaffarian D., Bryson C.L., Lemaitre R.N., et al. Fish Intake and Risk of Incident Heart Failure. J Am Coll Cardiol. 2005;45:2015-2021.

286 GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230.

287 Mozaffarian D., Fonarow G. Statins and n-3 fatty acid supplementation in heart failure. 2008;372(9645):1195-1196.

288 Pauwels E.K., Kostkiewicz M. Fatty acid facts, part III: Cardiovascular disease, or, a fish diet is noy fishy. Drug News Persp. 2008;21(10):552-561.

289 Olgar S., Ertugrul T., et al. Fish oil supplementation improves left ventricular function in children with idiopathic dilated cardiomyopathy. Congest Heart Fail. 2007;13(6):308-312.

290 Stepura O.B., Martynow A.I. Magnesium orotate in severe congestive heart failutre (MACH). Int J Cardiol. 2009;131(2):293-295.

291 Almoznino-Sarafian D., et al. Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr. 2007;46(4):230-237.

292 Chen J., Wu G., Li S., Yu T., Xie Y., Zhou L., Wang L. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database of Systematic Reviews. (Issue 4):2007. Art. No.: CD005052. doi: 10.1002/14651858.CD005052.pub2

293 Pittler M.H., Guo R., Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database of Systematic Reviews. (Issue 1):2008. Art. No.: CD005312. doi: 10.1002/14651858.CD005312.pub2

294 Glynn R.J., Ridker P.M., et al. Effects of Random Allocation to vitamin E Supplementation on the Occurrence of Venous Thromboembolism. Report From the Women’s Health Study. Circulation. 2007;116:1497-1503.

295 Galal W., van Gestel I., Hoeks S.E., et al. The obesity paradox in patients with peripheral arterial disease. Chest. 2008;134:925-930.

296 Jablecka A., Checiński P., Krauss H., et al. The influence of two different doses of L-arginine oral supplementation on nitric oxide (NO) concentration and total antioxidant status (TAS) in atherosclerotic patients. Med Sci Monit. 2004;10(1):CR29-CR32.

297 He F.J., Nowson C.A., MacGregor G.A. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006;367:320-326.

298 Särkämö T., Tervaniemi M., Laitinen S., et al. Music listening enhances cognitive recovery and mood after middle cerebral artery stroke. Brain. 2008;131(Pt 3):866-876.

299 Legg L.A., Drummond A.E., Langhorne P. Occupational therapy for patients with problems in activities of daily living after stroke. Cochrane Database Syst Rev. (4):2006 Oct 18. CD003585

300 Rabadi M.H., Coar P.L., et al Lukin M. Intensive nutritional supplements can improve outcomes in stroke rehabilitation. Neurology. 2008;71(23):1856-1861.

301 Chan Y.H., Lau K.K., Yiu K.H., et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. Eur Heart J. 2008;29(22):2800-2807.

302 Vitetta L, Harris E, Kirk J, Pipingas A, Sali A. Cognitive Decline in at Risk Adults and the Effect of a Multivitamin/Mineral Supplement. (Abs) Heart Foundation Proceedings 2009;P109.

303 Jordan J.E., Osborne R.H. Chronic disease self-management education programs: challenges ahead. MJA. 2007;186(2):84-87.

304 Mager A., Orvin K., Koren-Morag N., et al. Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. Am J Cardiol. 2009;104(6):745-749.